Infinity Pharmaceuticals is a biopharmaceutical company that develops cancer medicines. Its product candidate, IPI-549, is a clinical-stage immuno-oncology product that inhibits an enzyme and is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer. The company has strategic alliances with other pharmaceutical companies and is headquartered in Cambridge, Massachusetts.